McKesson (MCK) was upgraded to "Overweight" from "Neutral" at JPMorgan today.

Shares of the San Francisco-based company that's engaged in delivering pharmaceuticals, medical supplies and healthcare information technology were up about 2% in early morning trading.

JPMorgan analyst Lisa Gill also raised her price target on the shares to $189 from $167.

The analyst believes additional value should be unlocked from the Change transaction and that the valuation discount versus peers is unwarranted.

Last week McKesson reported fourth-quarter fiscal 2017 adjusted earnings that exceeded analysts' expectations.

Stocks have rebounded following a sharp sell off last week. Jim Cramer believes the rebound is real and gives investors advice on how to play the market going forward.

If you liked this article you might like

How World's Largest Drug Distributor Is Helping Harvey Victims Treat Snakebites

J&J Enters Death Penalty Debate, Protests Use of Drug in Lethal Injection

Eclipse in the USA: Then and Now

Finding Value in a Pricey Environment

Allscripts Stock Climbs, Cantor Upgrades After McKesson Deal